FRISCO, TEXAS -- (MARKET WIRE) -- 03/11/11 -- Allezoe Medical Holdings, Inc. (OTCBB: ALZM) announces that it has acquired Organ Transport Systems, Inc. (OTS) from Healthcare of Today, Inc. in an all stock transaction. The acquisition of OTS is the first of several planned acquisitions by Allezoe Medical Holdings ("Allezoe") in the medical device development, manufacturing and related services market. As a result of the acquisition, Michael Holder, President, CEO and Director of OTS, and Hyman White, Secretary, Treasurer and Director of OTS, have been appointed to the Board of Directors of ALZM. Mr. Holder will serve as the CEO of Allezoe and Mr. White as its Secretary and Treasurer.
OTS plans to redefine human donor organ procurement through better organ preservation, with its LifeCradle® product line. OTS has developed, patented and is in the process of commercializing a portable hypothermic, oxygenated preservation and transport system for human organs. The OTS LifeCradle® technology has been developed to provide a safe and cost effective method to transport human organs for transplant purposes, and improve upon the surprisingly low percentage of donated organs that are actually utilized in transplantation globally, largely due to the failures of the currently available preservation and transport methods.
Current statistics show that only 27% of donated hearts and only 9% of donated lungs actually can be transplanted for various reasons, many of which OTS addresses with its medical devices. The OTS LifeCradle® technology has already been shown in pre-clinical studies to significantly increase preservation time and improve the condition of transplanted animal hearts compared with the current systems in use. These studies have been presented at national and international professional society conferences and published in major peer-reviewed professional society publications, such as the Journal of Heart & Lung Transplantation.
New Allezoe CEO Michael Holder says, "With the acquisition of Organ Transport by Allezoe Medical, we believe we are positioned to be a biotechnology leader and that our highly skilled leadership and business strategy is suited for introduction to the marketplace. We believe this marriage of opportunity and expertise will prove rewarding for our shareholders as well as the many transplant patients we expect to serve."
FORWARD LOOKING STATEMENT
This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.
No comments:
Post a Comment